FindTrial
Sign In

Allopurinol in kidney disease

Allopurinol for CVD in CKD (AvoiD-CKD): A double blind, randomized controlled trial - AvoiD-CKD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025044
Enrollment
4630
Registered
2020-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 2: N184- Chronic kidney disease, stage 4 (severe) Health Condition 3: N185- Chronic kidney disease, stage 5

Interventions

Intervention1: Allopurinol: Dose 100 mg Frequency Once every day Route Oral Duration 36 months Control Intervention1: Placebo: Matching placebo every day Control Intervention2: Placebo: Dose Not appl

Sponsors

Head Department of Nephrology PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years 2. eGFR by CKD-EPI 10-45 ml/min/1.73m2 3. Serum uric acid levels more than or equal to 6 mg/dL 4. Clinically stable course as judged by the treating physician for last 3 months

Exclusion criteria

Exclusion criteria: 1. Receiving long-term maintenance dialysis 2. Receiving immunosuppressive therapy 3. Diagnosis of gout 4. Diagnosis of chronic liver disease 5. Anticipated to need long-term renal replacement therapy within 6 months as judged by treating physician 6. Poor functional status as judged by the treating physician 7. Life expectancy 8. Pregnancy or planning of pregnancy in case of females 9. Blood Hemoglobin 10. History of having received any type of organ transplant 11. Diagnosis of malignancy 12. History of allergy/hypersensitivity reaction to allopurinol 13. Having received hypouricemic drug in last 30 days

Design outcomes

Primary

MeasureTime frame
Primary outcome measure will be a composite of MACE that includes new onset heart failure, CAD, PVD, cerebrovascular accident (transient ischemic attack or stroke), any coronary or peripheral arterial revascularization procedure and death due to CVD.Timepoint: 36 months—

Secondary

MeasureTime frame
Composite of 50% decline in GFR and need of RRTTimepoint: 36 months;Composite of all-cause death and non-fatal MACETimepoint: 36 months;Need of RRTTimepoint: 36 months—

Countries

India

Contacts

Public ContactDr Vivek Kumar

Postgraduate Institute of Medical Education and Research, Chandigarh

enigma165@yahoo.co.in7087429731

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026